Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation
Abstract
:1. Introduction
2. Inflammatory Bowel Disease
3. Multiple Sclerosis
4. Rheumatoid Arthritis
5. Conclusions
Conflicts of Interest
References
- Holick, M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 2006, 81, 353–373. [Google Scholar] [CrossRef] [PubMed]
- Trang, H.M.; Cole, D.E.; Rubin, L.A.; Pierratos, A.; Siu, S.; Vieth, R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 1998, 68, 854–858. [Google Scholar] [PubMed]
- Houghton, L.A.; Vieth, R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin. Nutr. 2006, 84, 694–697. [Google Scholar] [PubMed]
- Holick, M.F.; Biancuzzo, R.M.; Chen, T.C.; Klein, E.K.; Young, A.; Bibuld, D.; Reitz, R.; Salameh, W.; Ameri, A.; Tannenbaum, A.D. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. Metab. 2008, 93, 677–681. [Google Scholar] [CrossRef] [PubMed]
- Heaney, R.P.; Recker, R.R.; Grote, J.; Horst, R.L.; Armas, L.A. Vitamin D3 is more potent than vitamin D2 in humans. J. Clin. Endocrinol. Metab. 2001, 96, E447–E452. [Google Scholar] [CrossRef]
- Chowdhury, R.; Kunutsor, S.; Vitezova, A.; Oliver-Williams, C.; Chowdhury, S.; Kiefte-de-Jong, J.C.; Khan, H.; Baena, C.P.; Prabhakaran, D.; Hoshen, M.B.; et al. Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014, 348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhalla, A.K.; Amento, E.P.; Clemens, T.L.; Holick, M.F.; Krane, S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 1983, 57, 1308–1310. [Google Scholar] [CrossRef] [PubMed]
- Provvedini, D.M.; Tsoukas, C.D.; Deftos, L.J.; Manolagas, S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221, 1181–1183. [Google Scholar] [CrossRef] [PubMed]
- Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch. Biochem. Biophys. 2000, 374, 334–338. [Google Scholar] [CrossRef] [PubMed]
- Griffin, M.D.; Lutz, W.; Phan, V.A.; Bachman, L.A.; McKean, D.J.; Kumar, R. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 6800–6805. [Google Scholar] [CrossRef] [PubMed]
- Griffin, M.D.; Lutz, W.H.; Phan, V.A.; Bachman, L.A.; McKean, D.J.; Kumar, R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 2000, 270, 701–708. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179, 1634–1647. [Google Scholar] [CrossRef] [PubMed]
- Boonstra, A.; Barrat, F.J.; Crain, C.; Heath, V.L.; Savelkoul, H.F.; O’Garra, A. 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001, 167, 4974–4980. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, G.B.; van Etten, E.; Verstuyf, A.; Waer, M.; Overbergh, L.; Gysemans, C.; Mathieu, C. 1,25-Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab. Res. Rev. 2011, 27, 933–941. [Google Scholar] [CrossRef] [PubMed]
- Hamzaoui, A.; Berraïes, A.; Hamdi, B.; Kaabachi, W.; Ammar, J.; Hamzaoui, K. Vitamin D reduces the differentiation and expansion of Th17 cells in young asthmatic children. Immunobiology 2014, 219, 873–879. [Google Scholar] [CrossRef] [PubMed]
- Urry, Z.; Chambers, E.S.; Xystrakis, E.; Dimeloe, S.; Richards, D.F.; Gabryšová, L.; Christensen, J.; Gupta, A.; Saglani, S.; Bush, A.; et al. The role of 1alpha,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur. J. Immunol. 2012, 42, 2697–2708. [Google Scholar] [CrossRef] [PubMed]
- Kang, S.W.; Kim, S.H.; Lee, N.; Lee, W.W.; Hwang, K.A.; Shin, M.S.; Lee, S.H.; Kim, W.U.; Kang, I. 1,25-dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J. Immunol. 2012, 188, 5276–5282. [Google Scholar] [CrossRef] [PubMed]
- Urry, Z.; Xystrakis, E.; Richards, D.F.; McDonald, J.; Sattar, Z.; Cousins, D.J.; Corrigan, C.J.; Hickman, E.; Brown, Z.; Hawrylowicz, C.M. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J. Clin. Invest. 2009, 119, 387–398. [Google Scholar] [PubMed]
- Cippitelli, M.; Santoni, A. Vitamin D3: A transcriptional modulator of the interferon-gamma gene. Eur. J. Immunol. 1998, 28, 3017–3030. [Google Scholar] [CrossRef] [PubMed]
- Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173, 2909–2912. [Google Scholar] [CrossRef] [PubMed]
- Schwalfenberg, G.K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol. Nutr. Food Res. 2011, 55, 96–108. [Google Scholar] [CrossRef] [PubMed]
- Wobke, T.K.; Sorg, B.L.; Steinhilber, D. Vitamin D in inflammatory diseases. Front. Physiol. 2014, 5. [Google Scholar] [CrossRef] [PubMed]
- Loftus, E.V., Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126, 1504–1517. [Google Scholar] [CrossRef] [PubMed]
- Khalili, H.; Huang, E.S.; Ananthakrishnan, A.N.; Higuchi, L.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012, 61, 1686–1692. [Google Scholar] [CrossRef] [PubMed]
- Ananthakrishnan, A.N.; Khalili, H.; Higuchi, L.M.; Bao, Y.; Korzenik, J.R.; Giovannucci, E.L.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology 2012, 142, 482–489. [Google Scholar] [CrossRef] [PubMed]
- Curran, M.E.; Lau, K.F.; Hampe, J.; Schreiber, S.; Bridger, S.; Macpherson, A.J.; Cardon, L.R.; Sakul, H.; Harris, T.J.; Stokkers, P.; et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998, 115, 1066–1071. [Google Scholar] [CrossRef] [PubMed]
- Duerr, R.H.; Barmada, M.M.; Zhang, L.; Davis, S.; Preston, R.A.; Chensny, L.J.; Brown, J.L.; Ehrlich, G.D.; Weeks, D.E.; Aston, C.E. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am. J. Hum. Genet. 1998, 63, 95–100. [Google Scholar] [CrossRef] [PubMed]
- Satsangi, J.; Parkes, M.; Louis, E.; Hashimoto, L.; Kato, N.; Welsh, K.; Terwilliger, J.D.; Lathrop, G.M.; Bell, J.I.; Jewell, D.P. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat. Genet. 1996, 14, 199–202. [Google Scholar] [CrossRef] [PubMed]
- Simmons, J.D.; Mullighan, C.; Welsh, K.I.; Jewell, D.P. Vitamin D receptor gene polymorphism: Association with Crohn’s disease susceptibility. Gut 2000, 47, 211–214. [Google Scholar] [CrossRef] [PubMed]
- Garg, M.; Rosella, O.; Lubel, J.S.; Gibson, P.R. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19, 2634–2643. [Google Scholar] [CrossRef] [PubMed]
- Martineau, A.; Jolliffe, D. “Vitamin D and human health: From the gamete to the grave”: Report on a meeting held at Queen Mary University of London, 23rd–25th April 2014. Nutrients 2014, 6, 2759–2919. [Google Scholar] [CrossRef]
- Jorgensen, S.P.; Hvas, C.L.; Agnholt, J.; Christensen, L.A.; Heickendorff, L.; Dahlerup, J.F. Active Crohn’s disease is associated with low vitamin D levels. J. Crohn’s Colitis 2013, 7, e407–e413. [Google Scholar] [CrossRef]
- Ananthakrishnan, A.N.; Cagan, A.; Gainer, V.S.; Cai, T.; Cheng, S.C.; Savova, G.; Chen, P.; Szolovits, P.; Xia, Z.; de Jager, P.L.; et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm. Bowel Dis. 2013, 19, 1921–1927. [Google Scholar] [PubMed]
- Veit, L.E.; Maranda, L.; Fong, J.; Nwosu, B.U. The vitamin D status in inflammatory bowel disease. PLoS One 2014, 9, e101583. [Google Scholar] [CrossRef] [PubMed]
- Kelly, P.; Suibhne, T.N.; O’Morain, C.; O’Sullivan, M. Vitamin D status and cytokine levels in patients with Crohn’s disease. Int. J. Vitam. Nutr. Res. 2011, 81, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Bartels, L.E.; Jørgensen, S.P.; Agnholt, J.; Kelsen, J.; Hvas, C.L.; Dahlerup, J.F. 1,25-dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn’s disease. Int. Immunopharmacol. 2007, 7, 1755–1764. [Google Scholar] [CrossRef] [PubMed]
- Ananthakrishnan, A.N.; Cheng, S.C.; Cai, T.; Cagan, A.; Gainer, V.S.; Szolovits, P.; Shaw, S.Y.; Churchill, S.; Karlson, E.W.; Murphy, S.N.; et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2014, 12, 821–827. [Google Scholar] [CrossRef] [PubMed]
- Tao, Q.; Wang, B.; Zheng, Y.; Jiang, X.; Pan, Z.; Ren, J. Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-Beta1/Smad3 pathway. Dig. Dis. Sci. 2014. [Google Scholar] [CrossRef]
- Cantorna, M.T.; Munsick, C.; Bemiss, C.; Mahon, B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 2000, 130, 2648–2652. [Google Scholar] [PubMed]
- Zhu, Y.; Mahon, B.D.; Froicu, M.; Cantorna, M.T. Calcium and 1α,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 2005, 35, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Glenn, A.J.; Fielding, K.A.; Chen, J.; Comelli, E.M.; Ward, W.E. Long-term vitamin D3 supplementation does not prevent colonic inflammation or modulate bone health in IL-10 knockout mice at young adulthood. Nutrients 2014, 6, 3847–3862. [Google Scholar] [CrossRef] [PubMed]
- Froicu, M.; Zhu, Y.; Cantorna, M.T. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 2006, 117, 310–318. [Google Scholar] [CrossRef] [PubMed]
- Meeker, S.; Seamons, A.; Paik, J.; Treuting, P.M.; Brabb, T.; Grady, W.M.; Maggio-Price, L. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res. 2014, 74, 4398–4408. [Google Scholar] [CrossRef] [PubMed]
- Larmonier, C.B.; McFadden, R.M.; Hill, F.M.; Schreiner, R.; Ramalingam, R.; Besselsen, D.G.; Ghishan, F.K.; Kiela, P.R. High vitamin D3 diet administered during active colitis negatively affects bone metabolism in an adoptive T cell transfer model. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, G35–G46. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; Zhang, Y.G.; Lu, R.; Xia, Y.; Zhou, D.; Petrof, E.O.; Claud, E.C.; Chen, D.; Chang, E.B.; Carmeliet, G.; et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 2014. [Google Scholar] [CrossRef]
- Kong, J.; Zhang, Z.; Musch, M.W.; Ning, G.; Sun, J.; Hart, J.; Bissonnette, M.; Li, Y.C. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G208–G216. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Zhang, H.; Wu, H.; Li, H.; Liu, L.; Guo, J.; Li, C.; Shih, D.Q.; Zhang, X. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 2012, 12. [Google Scholar] [CrossRef] [PubMed]
- Kaser, A.; Blumberg, R.S. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011, 140, 1738–1747. [Google Scholar] [CrossRef] [PubMed]
- Ooi, J.H.; Li, Y.; Rogers, C.J.; Cantorna, M.T. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J. Nutr. 2013, 143, 1679–1686. [Google Scholar] [CrossRef] [PubMed]
- Sartor, R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134, 577–594. [Google Scholar] [CrossRef] [PubMed]
- Jorgensen, S.P.; Agnholt, J.; Glerup, H.; Lyhne, S.; Villadsen, G.E.; Hvas, C.L.; Bartels, L.E.; Kelsen, J.; Christensen, L.A.; Dahlerup, J.F. Clinical trial: Vitamin D3 treatment in Crohn’s disease—A randomized double-blind placebo-controlled study. Aliment Pharmacol. Ther. 2010, 32, 377–383. [Google Scholar] [CrossRef] [PubMed]
- Miheller, P.; Muzes, G.; Hritz, I.; Lakatos, G.; Pregun, I.; Lakatos, P.L.; Herszényi, L.; Tulassay, Z. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn’s disease patients. Inflamm. Bowel Dis. 2009, 15, 1656–1662. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Weaver, V.; Smith, J.P.; Bingaman, S.; Hartman, T.J.; Cantorna, M.T. Therapeutic effect of vitamin D Supplementation in a pilot study of Crohn’s patients. Clin. Trans. Gastroenterol. 2013, 4, e33. [Google Scholar] [CrossRef]
- Raftery, T.; Lee, C.S.; Cox, G.; McNamara, D.; Healy, M.; O’Sullivan, M. Supplemental vitamin D in quiescent Crohn’s disease—Effects on quality of life, fatigue and muscle strength: Results from a double blind placebo controlled study. Proc. Nutr. Soc. 2013, 72, E177. [Google Scholar] [CrossRef]
- The Crohn’s Colitis Foundation of America (CCFA). CCFA Nutrition and IBD Recommendations; CCFA: New York, NY, USA, 2012. [Google Scholar]
- Karrasch, T.; Jobin, C. NF-kappaB and the intestine: Friend or foe? Inflamm. Bowel Dis. 2008, 14, 114–124. [Google Scholar] [CrossRef] [PubMed]
- Kaser, A.; Martinez-Naves, E.; Blumberg, R.S. Endoplasmic reticulum stress: Implications for inflammatory bowel disease pathogenesis. Curr. Opin. Gastroenterol. 2010, 26, 318–326. [Google Scholar] [CrossRef] [PubMed]
- Pithadia, A.B.; Jain, S. Treatment of inflammatory bowel disease (IBD). Pharmacol. Rep. 2011, 63, 629–642. [Google Scholar] [CrossRef] [PubMed]
- Simpson, S.; Blizzard, L.; Otahal, P.; van der Mei, I.; Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82, 1132–1141. [Google Scholar] [CrossRef] [PubMed]
- Ramagopalan, S.V.; Handel, A.E.; Giovannoni, G.; Rutherford Siegel, S.; Ebers, G.C.; Chaplin, G. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011, 76, 1410–1414. [Google Scholar] [CrossRef] [PubMed]
- Munger, K.L.; Levin, L.I.; Hollis, B.W.; Howard, N.S.; Ascherio, A. SErum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA J. Am. Med. Assoc. 2006, 296, 2832–2838. [Google Scholar] [CrossRef]
- Slomski, A. VItamin D levels appear to be robust predictor of ms progression. JAMA J. Am. Med. Assoc. 2014, 311, 790–790. [Google Scholar]
- Mowry, E.M.; Waubant, E.; McCulloch, C.E.; Okuda, D.T.; Evangelista, A.A.; Lincoln, R.R.; Gourraud, P.A.; Brenneman, D.; Owen, M.C.; Qualley, P.; et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann. Neurol. 2012, 72, 234–240. [Google Scholar] [CrossRef] [PubMed]
- Mowry, E.M.; Krupp, L.B.; Milazzo, M.; Chabas, D.; Strober, J.B.; Belman, A.L.; McDonald, J.C.; Oksenberg, J.R.; Bacchetti, P.; Waubant, E. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann. Neurol. 2010, 67, 618–624. [Google Scholar] [PubMed]
- Simpson, S.; Taylor, B.; Blizzard, L.; Ponsonby, A.L.; Pittas, F.; Tremlett, H.; Dwyer, T.; Gies, P.; van der Mei, I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010, 68, 193–203. [Google Scholar] [PubMed]
- Smolders, J.; Schuurman, K.G.; van Strien, M.E.; Melief, J.; Hendrickx, D.; Hol, E.M.; van Eden, C.; Luchetti, S.; Huitinga, I. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J. Neuropathol. Exp. Neurol. 2013, 72, 91–105. [Google Scholar] [CrossRef] [PubMed]
- Waschbisch, A.; Sanderson, N.; Krumbholz, M.; Vlad, G.; Theil, D.; Schwab, S.; Mäurer, M.; Derfuss, T. Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. PLoS One 2014, 9, e115488. [Google Scholar] [CrossRef] [PubMed]
- Bhargava, P.; Gocke, A.; Calabresi, P.A. 1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls. J. Neuroimmunol. 2015, 279, 20–24. [Google Scholar] [CrossRef] [PubMed]
- Peelen, E.; Damoiseaux, J.; Muris, A.H.; Knippenberg, S.; Smolders, J.; Hupperts, R.; Thewissen, M. Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol. Immunol. 2015, 63, 521–529. [Google Scholar] [CrossRef] [PubMed]
- Farias, A.S.; Spagnol, G.S.; Bordeaux-Rego, P.; Oliveira, C.O.; Fontana, A.G.; de Paula, R.F.; Santos, M.P.; Pradella, F.; Moraes, A.S.; Oliveira, E.C.; et al. Vitamin D3 induces IDO+ tolerogenic DCs and enhances treg, reducing the severity of EAE. CNS Neurosci. Ther. 2013, 19, 269–277. [Google Scholar] [CrossRef] [PubMed]
- Farsani, Z.S.; Behmanesh, M.; Sahraian, M.A. Interleukin-10 but not transforming growth factor-beta1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients. J. Neurol. Sci. 2015, 350, 18–23. [Google Scholar] [CrossRef] [PubMed]
- Burton, J.M.; Kimball, S.; Vieth, R.; Bar-Or, A.; Dosch, H.M.; Cheung, R.; Gagne, D.; D’Souza, C.; Ursell, M.; O’Connor, P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74, 1852–1859. [Google Scholar] [CrossRef] [PubMed]
- Wingerchuk, D.M.; Lesaux, J.; Rice, G.P.A.; Kremenchutzky, M.; Ebers, G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2005, 76, 1294–1296. [Google Scholar] [CrossRef] [PubMed]
- Kimball, S.M.; Ursell, M.R.; O’Connor, P.; Vieth, R. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007, 86, 645–651. [Google Scholar] [PubMed]
- Jagannath, V.A.; Fedorowicz, Z.; Asokan, G.V.; Robak, E.W.; Whamond, L. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst. Rev. 2010, 12, CD008422. [Google Scholar] [PubMed]
- Faridar, A.; Eskandari, G.; Sahraian, M.; Minagar, A.; Azimi, A. Vitamin D and multiple sclerosis: A critical review and recommendations on treatment. Acta Neurol. Belg. 2012, 112, 327–333. [Google Scholar] [CrossRef] [PubMed]
- Soilu-Hänninen, M.; Aivo, J.; Lindström, B.M.; Elovaara, I.; Sumelahti, M.L.; Färkkilä, M.; Tienari, P.; Atula, S.; Sarasoja, T.; Herrala, L.; et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1B in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Achiron, A.; Givon, U.; Magalashvili, D.; Dolev, M.; Liraz Zaltzman, S.; Kalron, A.; Stern, Y.; Mazor, Z.; Ladkani, D.; Barak, Y. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult. Scler. 2014. [Google Scholar] [CrossRef]
- Bhargava, P.; Cassard, S.; Steele, S.U.; Azevedo, C.; Pelletier, D.; Sugar, E.A.; Waubant, E.; Mowry, E.M. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp. Clin. Trials 2014, 39, 288–293. [Google Scholar] [CrossRef] [PubMed]
- Hiraki, L.T.; Arkema, E.; Cui, J.; Malspeis, S.; Costenbader, K.H.; Karlson, E.W. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. Rheumatology 2014, 53, 2243–2248. [Google Scholar] [CrossRef] [PubMed]
- Cote, J.; Berger, A.; Kirchner, L.H.; Bili, A. Low vitamin D level is not associated with increased incidence of rheumatoid arthritis. Rheumatol. Int. 2014, 34, 1475–1479. [Google Scholar] [CrossRef] [PubMed]
- Costenbader, K.H.; Feskanich, D.; Holmes, M.; Karlson, E.W.; Benito-Garcia, E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 2008, 67, 530–535. [Google Scholar] [CrossRef] [PubMed]
- Rossini, M.; Maddali Bongi, S.; la Montagna, G.; Minisola, G.; Malavolta, N.; Bernini, L.; Cacace, E.; Sinigaglia, L.; di Munno, O.; Adami, S. Vitamin D deficiency in rheumatoid arthritis: Prevalence, determinants and associations with disease activity and disability. Arth. Res. Ther. 2010, 12, R216. [Google Scholar] [CrossRef]
- Matsumoto, Y.; Sugioka, Y.; Tada, M.; Okano, T.; Mamoto, K.; Inui, K.; Habu, D.; Koike, T. Relationships between serum 25-hydroxycalciferol, vitamin D intake and disease activity in patients with rheumatoid arthritis—TOMORROW study. Mod. Rheumatol. 2015, 25, 246–250. [Google Scholar] [CrossRef] [PubMed]
- Grazio, S.; Naglić, Đ.B.; Anić, B.; Grubišić, F.; Bobek, D.; Bakula, M.; Kavanagh, H.S.; Kuna, A.T.; Cvijetić, S. Vitamin D serum level, disease activity and functional ability in different rheumatic patients. Am. J. Med. Sci. 2015, 349, 46–49. [Google Scholar] [CrossRef] [PubMed]
- Hong, Q.; Xu, J.; Xu, S.; Lian, L.; Zhang, M.; Ding, C. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology 2014, 53, 1994–2001. [Google Scholar] [CrossRef] [PubMed]
- Sabbagh, Z.; Markland, J.; Vatanparast, H. Vitamin D status is associated with disease activity among rheumatology outpatients. Nutrients 2013, 5, 2268–2275. [Google Scholar] [CrossRef] [PubMed]
- Merlino, L.A.; Curtis, J.; Mikuls, T.R.; Cerhan, J.R.; Criswell, L.A.; Saag, K.G.; Iowa Women’s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. Arthritis Rheum. 2004, 50, 72–77. [Google Scholar] [CrossRef] [PubMed]
- Kostoglou-Athanassiou, I.; Athanassiou, P.; Lyraki, A.; Raftakis, I.; Antoniadis, C. Vitamin D and rheumatoid arthritis. Ther. Adv. Endocrinol. Metab. 2012, 3, 181–187. [Google Scholar] [CrossRef] [PubMed]
- Baykal, T.; Senel, K.; Alp, F.; Erdal, A.; Ugur, M. Is there an association between serum 25-hydroxyvitamin D concentrations and disease activity in rheumatoid arthritis? Bratisl. Lekarsk. Listy 2012, 113, 610–611. [Google Scholar]
- Song, G.G.; Bae, S.C.; Lee, Y.H. Association between vitamin D intake and the risk of rheumatoid arthritis: A meta-analysis. Clin. Rheumatol. 2012, 31, 1733–1739. [Google Scholar] [CrossRef] [PubMed]
- Patel, S.; Farragher, T.; Berry, J.; Bunn, D.; Silman, A.; Symmons, D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007, 56, 2143–2149. [Google Scholar] [CrossRef] [PubMed]
- Haga, H.J.; Schmedes, A.; Naderi, Y.; Moreno, A.M.; Peen, E. Severe deficiency of 25-hydroxyvitamin D3 (25-OH-D3) is associated with high disease activity of rheumatoid arthritis. Clin. Rheumatol. 2013, 32, 629–633. [Google Scholar] [CrossRef] [PubMed]
- Higgins, M.J.; Mackie, S.L.; Thalayasingam, N.; Bingham, S.J.; Hamilton, J.; Kelly, C.A. The effect of vitamin D levels on the assessment of disease activity in rheumatoid arthritis. Clin. Rheumatol. 2013, 32, 863–867. [Google Scholar] [CrossRef] [PubMed]
- Als, O.S.; Riis, B.; Christiansen, C. Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin. Rheumatol. 1987, 6, 238–243. [Google Scholar] [CrossRef] [PubMed]
- Tizaoui, K.; Hamzaoui, K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology 2014. [Google Scholar] [CrossRef]
- Laragione, T.; Shah, A.; Gulko, P.S. The vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology. Mol. Med. 2012, 18, 194–200. [Google Scholar] [PubMed]
- Yarwood, A.; Martin, P.; Bowes, J.; Lunt, M.; Worthington, J.; Barton, A.; Eyre, S. Enrichment of vitamin D response elements in RA-associated loci supports a role for vitamin D in the pathogenesis of RA. Genes Immun. 2013, 14, 325–329. [Google Scholar] [CrossRef] [PubMed]
- Feng, X.; Lv, C.; Wang, F.; Gan, K.; Zhang, M.; Tan, W. Modulatory effect of 1,25-dihydroxyvitamin D3 on IL1 beta -induced RANKL, OPG, TNF alpha, and IL-6 expression in human rheumatoid synoviocyte MH7A. Clin. Dev. Immunol. 2013. [Google Scholar] [CrossRef]
- Luo, J.; Wen, H.; Guo, H.; Cai, Q.; Li, S.; Li, X. 1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. BioMed. Res. Int. 2013. [Google Scholar] [CrossRef]
- Ranganathan, P. Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis. J. Rheumatol. 2013, 40, 1529–1534. [Google Scholar] [CrossRef] [PubMed]
- Andjelkovic, Z.; Vojinovic, J.; Pejnovic, N.; Popovic, M.; Dujic, A.; Mitrovic, D.; Pavlica, L.; Stefanovic, D. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17, 453–456. [Google Scholar] [PubMed]
- Buckley, L.M.; Leib, E.S.; Cartularo, K.S.; Vacek, P.M.; Cooper, S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritisa randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1996, 125, 961–968. [Google Scholar] [CrossRef] [PubMed]
- O’Sullivan, M. Vitamin D as a novel therapy in inflammatory bowel disease: New hope or false dawn? Proc. Nutr. Soc. 2015, 74, 5–12. [Google Scholar] [CrossRef] [PubMed]
- Heaney, R.P. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr. Rev. 2014, 72, 48–54. [Google Scholar] [CrossRef] [PubMed]
- Cannell, J.; Grant, W.; Holick, M. Vitamin D and inflammation. Dermatoendocrinol 2014, 6, e983401–e983410. [Google Scholar] [CrossRef]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Goldsmith, J.R. Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation. Healthcare 2015, 3, 219-232. https://doi.org/10.3390/healthcare3020219
Goldsmith JR. Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation. Healthcare. 2015; 3(2):219-232. https://doi.org/10.3390/healthcare3020219
Chicago/Turabian StyleGoldsmith, Jason R. 2015. "Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation" Healthcare 3, no. 2: 219-232. https://doi.org/10.3390/healthcare3020219
APA StyleGoldsmith, J. R. (2015). Vitamin D as an Immunomodulator: Risks with Deficiencies and Benefits of Supplementation. Healthcare, 3(2), 219-232. https://doi.org/10.3390/healthcare3020219